This content is in French.
Birch allergy: could one shot change everything?
17 avril 2025
#AllergicRhinoconjunctivitis #IgG4 #Allergoid #BirchPollen #Immunotherapy
Allergic rhinoconjunctivitis (ARC) induced by birch pollen is one of the most common forms of seasonal allergic disease in Europe. It affects up to 40% of the population, with a high concentration of cases in temperate regions where birch trees are prevalent. This condition presents with a combination of eye symptoms (conjunctivitis, itching, tearing) and nasal symptoms (runny nose, sneezing, congestion), severely impacting quality of life, concentration, and sleep.
Allergic rhinoconjunctivitis (ARC) induced by birch pollen is one of the most common forms of seasonal allergic disease in Europe. It affects up to 40% of the population, with a high concentration of cases in temperate regions where birch trees are prevalent. This condition presents with a combination of eye symptoms (conjunctivitis, itching, tearing) and nasal symptoms (runny nose, sneezing, congestion), severely impacting quality of life, concentration, and sleep.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Mösges, R., et al. (2025). Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy. Allergy, 80(3), 817–826.
View the source
